{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:12:44Z","timestamp":1782778364192,"version":"3.54.5"},"reference-count":62,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijgc.2026.104495","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:31:51Z","timestamp":1768707111000},"page":"104495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating the oncologic impact of statin use in gynecologic cancers: a critical review of pre-clinical and clinical evidence"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1074-0229","authenticated-orcid":false,"given":"Paula","family":"Mateo-Kubach","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1168-2723","authenticated-orcid":false,"given":"M. Clara","family":"Sant\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6817-0693","authenticated-orcid":false,"given":"Heng-Cheng","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5458-9417","authenticated-orcid":false,"given":"Tommaso","family":"Meschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-8374","authenticated-orcid":false,"given":"Amy","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro T.","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8327-3535","authenticated-orcid":false,"given":"Behrouz","family":"Zand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2026.104495_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104495_bib2","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.leu.2402476","article-title":"HMG-CoA Reductase Inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis","volume":"16","author":"Wong","year":"2002","journal-title":"Leukemia"},{"issue":"48","key":"10.1016\/j.ijgc.2026.104495_bib3","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.1038\/onc.2012.6","article-title":"Targeting tumor cell metabolism with statins","volume":"31","author":"Clendening","year":"2012","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104495_bib4","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/bjc.2014.431","article-title":"In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells","volume":"111","author":"Jiang","year":"2014","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104495_bib5","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3892\/or.2015.3741","article-title":"Statins are potential anticancerous agents","volume":"33","author":"Altwairgi","year":"2015","journal-title":"Oncol Rep."},{"issue":"12","key":"10.1016\/j.ijgc.2026.104495_bib6","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/ph13120422","article-title":"Statins: HMG-CoA Reductase Inhibitors as potential anticancer agents against malignant neoplasms in women","volume":"13","author":"Markowska","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"issue":"19","key":"10.1016\/j.ijgc.2026.104495_bib7","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijgc.2026.104495_bib8","first-page":"1","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012","volume":"177","author":"Gu","year":"2014","journal-title":"NCHS Data Brief"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104495_bib9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jamacardio.2016.4700","article-title":"National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey","volume":"2","author":"Salami","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104495_bib10","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1158\/2767-9764.CRC-23-0549","article-title":"Synergistic effects of PARP inhibition and cholesterol biosynthesis pathway modulation","volume":"4","author":"Rutkowska","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104495_bib11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/2767-9764.CRC-24-0191","article-title":"Potential synergistic effect between niraparib and statins in ovarian cancer clinical trials","volume":"5","author":"Zhang","year":"2025","journal-title":"Cancer Res Commun"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104495_bib12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ygyno.2015.01.549","article-title":"Statin use and survival in elderly patients with endometrial cancer","volume":"137","author":"Yoon","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104495_bib13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/AOG.0000000000000926","article-title":"Association between statin use and endometrial cancer survival","volume":"126","author":"Nevadunsky","year":"2015","journal-title":"Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104495_bib14","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1002\/ijc.31625","article-title":"Statin use and mortality among endometrial cancer patients: a Danish nationwide cohort study","volume":"143","author":"Sperling","year":"2018","journal-title":"Int J Cancer"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104495_bib15","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.ygyno.2021.04.001","article-title":"Is there sufficient evidence to recommend women diagnosed with endometrial cancer take a statin: results from an Australian record-linkage study","volume":"161","author":"Feng","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"47","key":"10.1016\/j.ijgc.2026.104495_bib16","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013264","article-title":"The association between statin use and endometrial cancer survival outcome: a meta-analysis","volume":"97","author":"Li","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104495_bib17","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ygyno.2008.06.007","article-title":"Impact of statin therapy on survival in epithelial ovarian cancer","volume":"111","author":"Elmore","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104495_bib18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ygyno.2013.05.025","article-title":"The effect of statins on risk and survival of gynecological malignancies","volume":"130","author":"Lavie","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104495_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104521","article-title":"Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis","volume":"9","author":"Habis","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104495_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/ijc.30738","article-title":"Statin use and mortality among ovarian cancer patients: a population-based cohort study","volume":"141","author":"Verdoodt","year":"2017","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104495_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0189233","article-title":"Statin use is associated with improved survival in ovarian cancer: a retrospective population-based study","volume":"12","author":"Couttenier","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104495_bib22","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ygyno.2017.05.009","article-title":"Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer","volume":"146","author":"Vogel","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104495_bib23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/bcp.13559","article-title":"Impact of postdiagnostic statin use on ovarian cancer mortality: a systematic review and meta-analysis of observational studies","volume":"84","author":"Li","year":"2018","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104495_bib24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.ygyno.2021.05.021","article-title":"Cardiovascular medications and survival in people with ovarian cancer: a population-based cohort study from British Columbia, Canada","volume":"162","author":"Hanley","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104495_bib25","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41416-021-01460-4","article-title":"Statin use and survival among women with ovarian cancer: an Australian national data-linkage study","volume":"125","author":"Feng","year":"2021","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104495_bib27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3892\/ol.2022.13648","article-title":"Statin use improves the prognosis of ovarian cancer: an updated and comprehensive meta-analysis","volume":"25","author":"Wang","year":"2022","journal-title":"Oncol Lett"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104495_bib28","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1097\/IGC.0000000000001046","article-title":"Would lipophilic statin therapy as a prognostic factor improve survival in patients with uterine cervical cancer?","volume":"27","author":"Song","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104495_bib29","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104495_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2022.08.014","article-title":"Cardiovascular disease diagnoses among older women with endometrial cancer","volume":"167","author":"Anderson","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104495_bib31","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ygyno.2014.05.015","article-title":"Simvastatin, an HMG-CoA Reductase Inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer","volume":"134","author":"Schointuch","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104495_bib32","unstructured":"Cancer stat facts: ovarian cancer. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Accessed April 12, 2024. https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html."},{"issue":"9","key":"10.1016\/j.ijgc.2026.104495_bib33","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.3390\/curroncol30090609","article-title":"Dysregulation of cholesterol homeostasis in ovarian cancer","volume":"30","author":"Qusairy","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.ijgc.2026.104495_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.738177","article-title":"Aberrant cholesterol metabolism in ovarian cancer: identification of novel therapeutic targets","volume":"11","author":"He","year":"2021","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104495_bib35","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1530\/ERC-18-0572","article-title":"Hosts. Host CYP27A1 expression is essential for ovarian cancer progression","volume":"26","author":"He","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ijgc.2026.104495_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.682911","article-title":"Cholesterol metabolic reprogramming in cancer and its pharmacological modulation as therapeutic strategy","volume":"11","author":"Giacomini","year":"2021","journal-title":"Front Oncol"},{"issue":"39","key":"10.1016\/j.ijgc.2026.104495_bib37","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1038\/s41388-020-01432-7","article-title":"Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications","volume":"39","author":"Wei","year":"2020","journal-title":"Oncogene"},{"issue":"30","key":"10.1016\/j.ijgc.2026.104495_bib38","doi-asserted-by":"crossref","first-page":"47343","DOI":"10.18632\/oncotarget.10121","article-title":"Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer","volume":"7","author":"Greenaway","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104495_bib39","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/COC.0000000000000900","article-title":"Use of \u201crepurposed\u201d drugs in the treatment of epithelial ovarian cancer: a systematic review","volume":"45","author":"Goenka","year":"2022","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104495_bib40","first-page":"1015","volume":"29","author":"Wolfe","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ijgc.2026.104495_bib41","article-title":"Advances in ovarian cancer treatment using a combination of statins with other drugs","volume":"13","author":"Xia","year":"2022","journal-title":"Front Pharmacol"},{"issue":"25","key":"10.1016\/j.ijgc.2026.104495_bib42","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ijgc.2026.104495_bib43","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104495_bib44","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104495_bib45","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ijgc.2026.104495_bib46","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ijgc.2026.104495_bib47","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ijgc.2026.104495_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213937","article-title":"Statins as repurposed drugs in gynecological cancer: a review","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104495_bib48","first-page":"5252","article-title":"Atorvastatin suppresses the progression of cervical cancer via regulation of autophagy","volume":"12","author":"Sheng","year":"2020","journal-title":"Am J Transl Res"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104495_bib49","doi-asserted-by":"crossref","first-page":"411","DOI":"10.59566\/IJBS.2009.5411","article-title":"Statins inhibit the proliferation and induce cell death of human papilloma virus positive and negative cervical cancer cells","volume":"5","author":"Crescencio","year":"2009","journal-title":"Int J Biomed Sci"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104495_bib50","first-page":"3797","article-title":"Purification of lovastatin from Aspergillus terreus (KM017963) and evaluation of its anticancer and antioxidant properties","volume":"17","author":"Bhargavi","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104495_bib51","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/fcp.12479","article-title":"Simvastatin enhances chemotherapy in cervical cancer via inhibition of multiple prenylation-dependent GTPases-regulated pathways","volume":"34","author":"Pan","year":"2020","journal-title":"Fundam Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104495_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214408","article-title":"Regulatory mechanisms of fluvastatin and lovastatin for the p21 induction in human cervical cancer HeLa cells","volume":"14","author":"Lin","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104495_bib53","first-page":"1557","article-title":"Lovastatin inhibits the proliferation of human cervical cancer hela cells through the regulation of tp53 pathway by mir-92a-1-5p","volume":"35","author":"Hu","year":"2022","journal-title":"Pak J Pharm Sci"},{"issue":"14","key":"10.1016\/j.ijgc.2026.104495_bib54","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.3390\/ijms25147915","article-title":"Molecular mechanisms underlying the anticancer properties of pitavastatin against cervical cancer cells","volume":"25","author":"Chen","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104495_bib55","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ejca.2004.12.013","article-title":"A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix","volume":"41","author":"Knox","year":"2005","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104495_bib56","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.21873\/anticanres.14182","article-title":"Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer","volume":"40","author":"Svaton","year":"2020","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104495_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104495_bib58","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/CMR.0000000000000299","article-title":"Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma","volume":"26","author":"Failing","year":"2016","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104495_bib59","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3390\/ijms25010323","article-title":"Enhancing immunotherapy in ovarian cancer: the emerging role of metformin and statins","volume":"25","author":"Almeida-Nunes","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104495_bib60","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1957605","article-title":"The effect of concomitant use of statins, NSAIDs, low-dose aspirin, metformin and beta-blockers on outcomes in patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"10","author":"Zhang","year":"2021","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104495_bib61","article-title":"Statins and immunotherapy: togetherness makes strength The potential effect of statins on immunotherapy for NSCLC. Cancer rep","volume":"4","author":"Rossi","year":"2021","journal-title":"Cancer Rep (Hoboken)"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104495_bib62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/OP-24-00583","article-title":"Concomitant statin use and survival in patients with cancer on immune checkpoint inhibitors: a meta-analysis","volume":"21","author":"Liao","year":"2025","journal-title":"JCO Oncol Pract"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26000277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26000277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:36:59Z","timestamp":1777887419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26000277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1048891X26000277"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104495","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the oncologic impact of statin use in gynecologic cancers: a critical review of pre-clinical and clinical evidence","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104495"}}